[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
April 23/30, 2003

Lipid-Lowering Therapy and Risk of Coronary Events

JAMA. 2003;289(16):2070. doi:10.1001/jama.289.16.2071-a

To the Editor: The authors of ALLHAT-LLT1 only briefly mentioned the anti-inflammatory effect of statins. Both primary and secondary prevention trials24 have found that treatment with statins reduces levels of C-reactive protein (CRP) and cardiovascular risk, with the greatest beneficial effects in individuals with elevated baseline levels of CRP, a marker of inflammation. Furthermore, a recent study5 found that CRP level is a stronger predictor of cardiovascular events than low-density lipoprotein cholesterol level. Thus, baseline levels of CRP may have an important role in determining the beneficial effects of statins.